Announcement • May 23
Immix Biopharma Announces 95% Complete Response Rate In Interim Update From Relapsed/Refractory AL Amyloidosis Clinical Trial NEXICART-2 Immix Biopharma, Inc. announced that all four relapsed/refractory AL Amyloidosis MRD-negative patients presented at ASH 2025 have converted to complete response (CR). The NEXICART-2 CR rate is now 95% (19 out of 20 patients). All CRs were reached within 1 year of follow-up post-dosing. No relapses have been observed as of the date for patients who have reached CR. All subsequently enrolled patients for whom MRD results are available are MRD-negative at one month. The next NEXICART-2 update is expected late September 2026. These results support the Company’s plan to initiate a multi-center, randomized Phase 3 trial in newly diagnosed AL Amyloidosis patients. NEXICART-2 (NCT06097832) is a multi-site U.S. Phase 2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis, with a registrational design. NEXICART-2 is a 45-patient study. AL amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead continuously produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 38,500 patients in 2026. The Amyloidosis market was $3.6 billion in 2017, and is expected to reach $6 billion in 2025, according to Grand View Research as of 2023. NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy with a “digital filter” that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the FDA, and Orphan Drug Designation (ODD) by the US FDA and in the EU by the EMA. Announcement • May 22
Immix Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $150.000005 million. Immix Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $150.000005 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 16,778,524
Price\Range: $8.94
Discount Per Security: $0.5364 Announcement • May 21
Immix Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $150.000005 million. Immix Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $150.000005 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 16,778,524
Price\Range: $8.94
Transaction Features: Registered Direct Offering 
